Structural Basis for Transport and Inhibition of Nucleotide Sugar Transport in Pathogenic Fungi

Fungal infections affect over 1 billion people globally each year, with mortality rates exceeding 50% for invasive species like Aspergillus fumigatus and Candida albicans. Rising resistance to existing antifungals has created an urgent need for new therapeutic targets. One understudied but promising target is nucleotide sugar transport in pathogenic fungi, a process essential for building the fungal cell wall.

Recent breakthroughs in structural biology have revealed exactly how these transporters work, and how we can stop them. This article breaks down the latest research on the structural basis of nucleotide sugar transport and inhibition in pathogenic fungi, and what it means for the future of antifungal drug development.

What Is Nucleotide Sugar Transport?

Nucleotide sugars (like UDP-glucose, GDP-mannose) are the building blocks of fungal cell wall polysaccharides, including chitin and β-glucans. These molecules are synthesized in the fungal cytosol, but cell wall assembly occurs in the endoplasmic reticulum and Golgi apparatus.

To reach their site of action, nucleotide sugars must cross the ER/Golgi membrane via specialized nucleotide sugar transporters (NSTs). These are integral membrane proteins, most belonging to the major facilitator superfamily (MFS) of transporters.

Pathogenic fungi encode dozens of unique NSTs, each specific to a particular nucleotide sugar. Disrupting this transport process cripples cell wall synthesis, weakening the fungus and reducing its ability to infect hosts.

Why Target NSTs in Pathogenic Fungi?

Existing antifungal drug classes have significant limitations. Azoles target ergosterol synthesis but face widespread resistance. Echinocandins target β-glucan synthesis but are ineffective against some fungal species. NSTs offer several advantages as drug targets:

• No human homologs: Fungal NSTs have unique structural features not found in human nucleotide sugar transporters, minimizing off-target toxicity.
• Essential for virulence: Many NSTs are required for fungal pathogenicity, not just laboratory growth, meaning inhibitors can block infection without harming commensal fungi.
• Synergistic potential: NST inhibitors enhance the activity of existing echinocandins by limiting the substrate available for β-glucan synthesis.

Structural Insights Into Fungal NSTs

For decades, studying NSTs was challenging because they are membrane-embedded proteins that are difficult to purify and crystallize. Recent advances in cryo-electron microscopy (cryo-EM) have changed that.

High-resolution structures of NSTs from Candida albicans, Aspergillus fumigatus, and Cryptococcus neoformans have revealed their transport mechanism. NSTs alternate between two conformations:

1. Inward-open: The transporter binds nucleotide sugars from the cytosol, with conserved arginine and lysine residues forming hydrogen bonds with the nucleotide phosphate group.
2. Outward-open: The transporter releases the sugar into the ER/Golgi lumen, where it is used for cell wall polysaccharide synthesis.

These structures also identify a hydrophobic pocket that recognizes the specific sugar moiety of each nucleotide sugar, explaining why each NST is specific to a single substrate.

How Structural Data Drives NST Inhibition

With high-resolution NST structures in hand, researchers can use structure-based drug design to develop targeted inhibitors. Key strategies include:

• Virtual screening: Computational models of the NST substrate binding pocket are used to screen millions of small molecules for compounds that fit the pocket and block substrate binding.
• Covalent inhibitors: Molecules that form irreversible bonds with conserved residues in the transporter, providing long-lasting inhibition.
• Allosteric modulators: Compounds that bind to sites outside the substrate pocket to lock the transporter in an inactive conformation.

Early-stage inhibitors identified through these methods show potent activity against drug-resistant fungal strains in laboratory studies, with low toxicity to human cells.

Challenges and Future Directions

Despite progress, several hurdles remain for translating NST structural insights into clinical therapies:

• Redundancy: Pathogenic fungi often encode multiple NSTs for the same nucleotide sugar, requiring broad-spectrum inhibitors or combination therapies.
• Delivery: Systemic fungal infections require inhibitors that can reach deep tissues without being metabolized.
• Uncharacterized NSTs: Many fungal NSTs have unknown substrates, making it hard to predict which are essential for virulence.

Future work will leverage artificial intelligence to predict structures of uncharacterized NSTs, and design inhibitors that target multiple essential transporters at once.

Conclusion

Structural studies of nucleotide sugar transport in pathogenic fungi have opened a new avenue for antifungal drug development. By targeting a process unique to fungi, these inhibitors could address the growing crisis of antifungal resistance. As more NST structures are resolved, we can expect to see a pipeline of new therapies that save lives and reduce the burden of invasive fungal disease.